Biopharmaceutical company Repligen Corp. (Nasdaq:RGEN) said this morning that it will repurchase of up to 1.25 million shares of its common stock, stating that the program “reflects the confidence it has in its business.”

Shares were halted in pre-market trading. For detailed price information and recent news stories about Repligen, click RGEN.

For access to the full article, you must be a registered member - it's FREE.